MOTION
REVITALIZED
Introducing MOTYS
A new amniotic allograft
Every day at Bioventus we strive to develop and deliver orthobiologics to help people get moving again. MOTYS – from the Latin word motus, meaning motion – marks a significant leap forward: it is rich in relevant growth factors, holds remarkable potential, and is reliable in its consistency.
Explore the medical science
Rich in Growth Factors
MOTYS contains amnion, chorion, and umbilical cord tissue obtained from consented placental donation. By utilizing all three tissues, the donated gift is maximized, enabling utilization of all naturally available growth factors.
More than 50 unique growth factors and cytokines have been identified in MOTYS.1 MOTYS contains consistent notable levels of pro-anabolic (bFGF), anti-catabolic (TIMP-1,-2,-3), and anti-inflammatory (IL-1Ra) factors, and low levels of inflammatory factors (IL-1α).2-5
Remarkable Potential
MOTYS holds great potential as a biologic therapy, because it displays a multifactorial mechanism of action (MOA). This MOA may promote a beneficial combination of anti-inflammatory, anti-catabolic and pro-anabolic effects.3-5 These effects have been demonstrated through in vitro and in vivo data in a range of applications.*
Rich in Growth Factors
MOTYS contains amnion, chorion, and umbilical cord tissue obtained from consented placental donation. By utilizing all three tissues, the gift is maximized, enabling utilization of all naturally available growth factors.
Notable levels of key factors identified. MOTYS contains consistent notable levels of pro-anabolic (bFGF), anti-catabolic (TIMP-1,-2,-3), and anti-inflammatory (IL-1Ra) factors, and low levels of inflammatory factors (IL-1α).2-5
Remarkable Potential
MOTYS holds great potential as a biologic therapy, because it displays a multifactorial mechanism of action (MOA). This MOA may promote a beneficial combination of anti-inflammatory, anti-catabolic and pro-anabolic effects.3-5 These effects have been demonstrated through in vitro and in vivo data in a range of applications.*
Reliable Consistency
MOTYS was developed in partnership with a leading tissue bank, with a goal of providing a more consistent amniotic option. Through careful recovery, specialized processing and testing, MOTYS has demonstrated lot-to-lot consistency of naturally occurring biofactors.
MOTYS is:
Sterile, containing
no live cells
Stored at room
temperature
Easy to
reconstitute
GET IN TOUCH WITH US
To schedule time to speak with someone, please book by clicking here.
To receive an email with information, click here to fill out our form or call 1-800-836-4080
Stay up to date on MOTYS. Join our mailing list.
REFERENCES: 1. Bioventus LLC. Data on file, RPT-001100: PTP-001: Protein Content Analysis of Multiple Lots via Quantibody Multiplex Arrays.
2. Bioventus LLC. Data on file, RPT-001101: PTP-001: Validated ELISA Analysis of Multiple Lots.
3. Martin I, Vunjak-Novakovic G, Yang J, Langer R, Freed LE. Mammalian chondrocytes expanded in the presence of fibroblast growth factor 2 maintain the ability to differentiate and regenerate three-dimensional cartilaginous tissue. [ital journal abbreviation] Exp Cell Res. 1999;253(2):681-8. doi:10.1006/excr.1999.4708
4. Mehta S, Akhtar S, Porter RM, Önnerfjord P, Bajpayee AG. Interleukin-1 receptor antagonist (IL-1Ra) is more effective in suppressing cytokine-induced catabolism in cartilage-synovium co-culture than in cartilage monoculture. [ital journal abbreviation] Arthritis Res Ther. 2019;21(1):238. doi:10.1186/s13075-019-2003-y
5. Arpino V, Brock M, Gill SE. The role of TIMPs in regulation of extracellular matrix proteolysis. [ital journal abbreviation] Matrix Biol. 2015;44-46:247-54. doi:10.1016/j.matbio.2015.03.005
*In vitro and in vivo data may not be predictive of clinical performance.
MOTYS is a sterile allograft derived from human placental tissue matrix to supplement damaged or inadequate tissue.
MOTYS is a trademark of Bioventus LLC. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
®2020 Bioventus LLC All rights reserved. SMK-003258 10/20